PAT

HCLTech Delivers a Quarter of Strong Execution and Record Deal Bookings

Retrieved on: 
Thursday, October 12, 2023
Data Management, Security, Technology, Other Technology, Software, Artificial Intelligence, Internet, Climate change, Acquisition, Machine learning, ARR, Yoy, AI, LTM, FCF, Biodiversity, EBIT, CC, C Vijayakumar, Growth, Non-governmental organization, PAT, Optimism, Cloud computing, Quarter, ASAP, Video game, Medical device, HCLTech, INR

The company reported record deal bookings of $4 billion for the quarter.

Key Points: 
  • The company reported record deal bookings of $4 billion for the quarter.
  • 16 large deals (including one mega deal) — 10 in services and six in software — contributed to this milestone.
  • Our new bookings of $4 billion this quarter is at an all-time high, driven by a standout mega deal.
  • During the quarter, HCLTech took its highly successful HCLTech Grant program to the Americas.

IPSY Unveils Pat McGrath, the World's Preeminent Makeup Artist, as Icon Box's Latest Distinguished Curator

Retrieved on: 
Tuesday, October 10, 2023
Dark, Senior, PAT, Social media, Merchandising, Collection, McGrath, Creativity, Beauty, Individual, AR, SAN, Magic, Cosmetics

SAN MATEO, Calif., Oct. 10, 2023 /PRNewswire/ -- IPSY, the world's biggest beauty subscription powerhouse, announced today the launch of Icon Box by Pat McGrath. The globally acclaimed makeup artist and Pat McGrath Labs founder has made a name for herself in the industry for the last 20+ years, and now she's sharing her favorite products with the IPSY community through her exclusive Icon Box.

Key Points: 
  • SAN MATEO, Calif., Oct. 10, 2023 /PRNewswire/ -- IPSY , the world's biggest beauty subscription powerhouse, announced today the launch of Icon Box by Pat McGrath.
  • "Makeup is all about self-expression, individuality, and exploration into your own creativity," says McGrath.
  • "Our entire IPSY team was beyond excited to secure a true legend like Pat McGrath as our November Icon Box curator," says Kristy Westrup, IPSY's Senior Vice President of Merchandising and Brand Partnerships.
  • Exclusively available for Glam Bag and BoxyCharm members, Icon Box is a quarterly upgrade beloved by IPSY's most beauty-obsessed members.

Capital Rx's JUDI® Redefines the Role Technology Plays in the Administration of Medicare, Medicaid, and Commercial Pharmacy Programs

Retrieved on: 
Friday, October 6, 2023
CSID, Frustration, PBM, COVID, Feature, API, Health, Entrepreneurship, Medicare, PBA, Architecture, PAT, Physician, EHP, Health insurance, Cryptocurrency, Medicaid

With every core PBM function in JUDI® and the ability to rapidly deploy enhancements, clients save time and money.

Key Points: 
  • With every core PBM function in JUDI® and the ability to rapidly deploy enhancements, clients save time and money.
  • Launched in 2021 to improve costs and service levels in the commercial space, JUDI began processing Medicare claims on January 1, 2023.
  • This is another time-saving workflow enhancement that reduces the potential for errors and alleviates stress for health plan executives.
  • To learn more about Capital Rx's pharmacy benefit administration capabilities and JUDI, please visit Capital Rx – JUDI® .

Hamilton Company Introduces VisiFerm™ SU, Redesign of Trusted Dissolved Oxygen Sensors for Single-Use

Retrieved on: 
Tuesday, October 3, 2023
Membrane, PAT, Electronics

BONADUZ, Switzerland, Oct. 3, 2023 /PRNewswire/ -- Hamilton Company, a specialist in automation technology and analytical sensors, today announced the introduction of its redesigned VisiFerm™ SU RS485-ECS to ensure supply safety.

Key Points: 
  • BONADUZ, Switzerland, Oct. 3, 2023 /PRNewswire/ -- Hamilton Company, a specialist in automation technology and analytical sensors, today announced the introduction of its redesigned VisiFerm™ SU RS485-ECS to ensure supply safety.
  • It is the newest member of Hamilton's range of solid-state optical dissolved oxygen (DO) sensors, celebrated for their robust, low maintenance, quick, and accurate measurements compared to polarographic DO sensors, which rely on sensitive membranes and liquid electrolytes.
  • VisiFerm™ SU enables our clients to experience the benefits of single-use workflow without sacrificing the accuracy or precision of the traditional technology."
  • Installation of polarographic DO sensors into single-use processes must be mediated by cumbersome probe assemblies, which are prone to contamination and leakage.

Pat Tillman Foundation Announces CEO Transition

Retrieved on: 
Tuesday, September 5, 2023
Education, Pat Tillman Foundation, COVID-19, Russell Reynolds Associates, PTF, Legacy, Entrepreneurship, PAT, Tillman, Tobacco, Management

CHICAGO, Sept. 5, 2023 /PRNewswire/ -- The Pat Tillman Foundation (PTF) announces today that Dan Futrell is transitioning out of his CEO role with the Foundation to focus on a new university model for higher education and his continued role as a Tillman Scholar.

Key Points: 
  • CHICAGO, Sept. 5, 2023 /PRNewswire/ -- The Pat Tillman Foundation (PTF) announces today that Dan Futrell is transitioning out of his CEO role with the Foundation to focus on a new university model for higher education and his continued role as a Tillman Scholar.
  • The Foundation thanks Dan for his significant efforts and leadership, especially during the challenging COVID-19 period, and wishes him and his family the very best.
  • The past four years have seen the community of Tillman Scholars grow to nearly 900, the launch of the Tillman Leadership Institute, and continued engagement with the broader community.
  • As a Tillman Scholar I'm excited about the future for the Foundation and look forward to seeing my peers at Pat's Run in April."

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy

Retrieved on: 
Friday, August 25, 2023
Journal of Palliative Medicine, PAT, JAMA Oncology, Cancer, Journal, University, DSM-IV codes, Research, Patient, Palliative care, Sunstone, Code, Pharmaceutical industry

The study analyzed audio and video data from a Phase 2 open label study looking at the effect of psilocybin therapy on patients with cancer and major depressive disorder.

Key Points: 
  • The study analyzed audio and video data from a Phase 2 open label study looking at the effect of psilocybin therapy on patients with cancer and major depressive disorder.
  • From the 2,074 minutes of video analyzed, the three coders in the study recorded 372 moments of therapeutic connection.
  • Manish Agrawal MD, Chief Executive Officer and Co-founder, Sunstone Therapies, and Co-author on the study, commented: “Discussion around psilocybin therapy is often focused on the drug.
  • This will have implications for training and quality measurement, and ultimately for how we deliver psychedelic therapies responsibly and safely.”

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

Retrieved on: 
Thursday, August 17, 2023
Maintenance, Partnership, SCADA, Therapy, Senior, Control system, Controller, Perfusion, Distributed control system, Supervisory control, Process analytical technology, Repligen, Repligen Corporation Award in Chemistry of Biological Processes, ATF, DCS, PAT, Sartorius, Software, Fine chemical

Customers experience optimized facility equipment installation, footprint, and maintenance requirements

Key Points: 
  • Customers experience optimized facility equipment installation, footprint, and maintenance requirements
    WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
  • The Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT).
  • The single, integrated controller provides easy integration into Supervisory Control and Data Acquisition (SCADA) and Distributed Control Systems (DCS).
  • “The market introduction of this integrated bioreactor–intensification system created in partnership with Repligen further reinforces Sartorius’ commitment to being an innovator in process intensification and demonstrates our expertise in upstream processing technologies,” said Mario Becker, Head of Product Group Bioreactor Technologies, Sartorius.

Global Cell and Gene Therapy Manufacturing QC Market Expected to Reach $10.65 Billion by 2033, Witnessing a CAGR of 16.85% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 16, 2023
Biotechnology, Genetics, Health, Gene, QC, NGS, Sartorius AG, Chromatography, Merck Group, MEA, Medicine, Research, Mass spectrometry, ELISA, Organization, Information International, Inc., CAR, QRM, Thermo Fisher Scientific, Patient safety, Flow cytometry, Kidney, Cell, PAT, LAL, Center for Urban and Regional Analysis, Electrophoresis, Therapy, Benchmarking, Eurofins Scientific, PCR, Safety, Automation, LATAM, Fine chemical, Pharmaceutical industry

The "Cell and Gene Therapy Manufacturing QC Market - A Global and Regional Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy Manufacturing QC Market - A Global and Regional Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global cell and gene therapy manufacturing QC market was valued at $1.95 billion in 2022 and is projected to reach $10.65 billion by 2033, with a CAGR of 16.85% during the forecast period from 2023 to 2033.
  • The demand for QC in cell and gene therapy manufacturing is driven by the growing production of therapies and increasing approvals for cell and gene therapies.
  • The global cell and gene therapy manufacturing QC market is on a growth trajectory, and key players are leveraging advancements in technology to drive improvements in product quality and safety.

Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening

Retrieved on: 
Tuesday, August 8, 2023
Depression, Q3, Royal Australian and New Zealand College of Psychiatrists, Quality of life, ASX, Diagnosis, PAT, PTSD, Nursing, Pharmaceutical industry, Clarion, Psychotherapy

MELBOURNE, Australia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that its subsidiary, Clarion Clinics Group Pty Ltd, is now accepting direct registration of interest in treatment from potential clients via its website at clarionclinics.com ahead of its planned Q3 opening.

Key Points: 
  • Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3 opening.
  • If accepted for treatment, clients will be treated for nine-months at a Clarion Clinic.
  • People who have an interest in treatment from Clarion can now register and request further information on the Clarion website.
  • At Clarion Clinics, our aim is to achieve the best outcomes possible using psychedelic therapies, through tailored and extended protocols and a brilliant team,” Dr. Paul Liknaitzky said.

Arkansas Children's Announces Largest Gift in System History

Retrieved on: 
Monday, August 7, 2023
Willard, Gastroenterology, Ear, Bed, Elective surgery, Eye, Tears, Health, ACH, Endoscopy, Fayetteville Public Library, Child, Nose, Operating, Hospital, Patient, Growth, PAT, NWA, Wellness, Truffle, Pharmaceutical industry, Hope, Arkansas Children's Hospital

SPRINGDALE, Ark., Aug. 7, 2023 /PRNewswire/ -- Arkansas Children's will further transform child health in northwest Arkansas through a $25 million investment from the Willard & Pat Walker Charitable Foundation, Inc. In recognition of this gift – the largest in Arkansas Children's history – the Arkansas Children's Northwest (ACNW) campus will be named the Pat Walker Campus. 

Key Points: 
  • In recognition of this gift – the largest in Arkansas Children's history – the Arkansas Children's Northwest (ACNW) campus will be named the Pat Walker Campus.
  • "Pat played such an integral role in making sure the children of Arkansas have every advantage they can have," said Macke.
  • This next step of where we're going with Arkansas Children's Northwest is part of our tribute."
  • In May, Arkansas Children's announced the expansion at its two hospitals as part of its commitment to make its highly specialized services more accessible for all Arkansas children, with an eye on Northwest Arkansas' accelerated growth.